Effect of Nonsteroidal Anti-inflammatory Drug (NSAID) in Disease Relapse, Progression, and Development of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Darmadi*, Imelda Rey

Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

ABSTRACT

This systematic review and meta-analysis investigated the association between nonsteroidal anti-inflammatory drugs (NSAIDs) and inflammatory bowel disease (IBD). Pooled analysis showed no significant association in disease relapse (OR 0.97; 95% CI 0.70–1.35; p = 0.86) and disease worsening (OR 2.06; 95% CI 0.92–4.57; p = 0.08) of existing IBD in patients receiving NSAID. In patients without prior IBD diagnosis, NSAID medication was significantly associated with the risk of new-onset IBD (OR 1.51; 95% CI 1.19–1.92; p = 0.0008). Given the varied effects of NSAIDs on IBD, careful management and consideration of dosage and frequency are essential in IBD patients. Despite these insights, the heterogeneity of study designs and small sample sizes in some cases call for further large-scale research to validate these findings.

Keywords: Inflammatory Bowel Disease, Nonsteroidal Anti-inflammatory Drug, Systematic Review, Meta-analysis

ABSTRAK

Studi ini mengevaluasi hubungan antara obat antiinflamasi nonsteroid (OAINS) terhadap inflammatory bowel disease (IBD). Meta-analisis menunjukkan tidak terdapat hubungan bermakna antara relapse (OR 0,97; 95% CI 0,70–1,35; p = 0,86) dan perburukan penyakit (OR 2,06; 95% CI 0.92–4.57; p = 0,08) pada pasien IBD yang mendapatkan OAINS. Pada pasien tanpa IBD yang mendapatkan OAINS pada pasien tanpa IBD sebelumnya, pemberian OAINS secara signifikan berkaitan dengan risiko terjadinya IBD baru (OR 1,51; 95% CI 1.19–1.92; p = 0,0008). Berkaitan dengan efek bervariasi terkait pemberian OAINS pada IBD, pertimbangan terkait dosis dan frekuensi OAINS penting dilakukan pada pasien IBD. Perlu diperhatikan terdapat heterogenitas dan jumlah sampel yang sedikit pada beberapa studi, sehingga penelitian lebih lanjut dibutuhkan untuk mengevaluasi hubungan antara OAINS dan IBD.

Kata Kunci: Inflammatory Bowel Disease, Obat Antiinflamasi Nonsteroid, Telaah Sistematik, Meta-analisis

*Corresponding author at: Faculty of Medicine, Universitas Sumatera Utara, Dr Mansyur S, Medan, North Sumatera, Indonesia

E-mail address: darmadi@usu.ac.id

Copyright ©2022 Published by Talenta Publisher, ISSN: 2686-0872 e-ISSN: 2686-0856
DOI: https://doi.org/10.32734/jetromi.v4i4.14473
Journal Homepage: https://jetromi.usu.ac.id
Attribution-NonCommercial-ShareAlike 4.0 International
1 Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder affecting the gastrointestinal tract, predominantly in the bowel. There are two subtypes of IBD, including Crohn’s disease and ulcerative colitis[1]. The exact cause of IBD remains unclear, although it has been reported to result from a complex interplay between genetic, immunological, host intestinal flora, and environmental factors (e.g., smoking or medication). There were approximately 4.9 million cases of IBD globally, which mostly occurred at the age of 15–30 years with 25% having the onset during adolescence[2], [3].

Patients with IBD may experience varying courses of disease, ranging from infrequent mild symptoms to intermittent or persistent symptoms with progressive disease. Patients may present with various gastrointestinal symptoms such as abdominal pain, diarrhea, rectal bleeding, tenesmus, or nutritional deficiencies[4]. Extra-intestinal manifestations had also been reported, including ophthalmologic (conjunctivitis, uveitis), hepatobiliary, and urologic involvement[5]. IBD is characterized by a cycle of relapse and remission, which results in a significant reduction in patient quality of life. Approximately 20% of all patients with IBD eventually develop steroid-refractory disease, while the remainder are dependent on steroids.[6]

Pain medications have been widely used in patients with IBD to alleviate their symptoms. However, the nonsteroidal anti-inflammatory drugs (NSAID) class has been thought to be associated with disease exacerbation or flare in IBD and the onset of IBD in patients without prior diagnosis of IBD[7]. However, previous meta-analyses reported inconsistent association between NSAID and exacerbation of IBD subtypes (Crohn’s disease or ulcerative colitis)[8]. Also, no study has carried out a meta-analysis regarding the development of new-onset IBD in NSAIDs. Therefore, this systematic review and meta-analysis aimed to evaluate the association of NSAID and IBD regarding all aspects, including but not limited to disease relapse, progression, and development of new-onset IBD in patients without prior IBD diagnosis.

2 Methods

2.1 Eligibility criteria and data extraction

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist[9]. Inclusion criteria included (1) studies evaluating the association between any NSAID and inflammatory bowel disease and (2) comparative studies between NSAID and any other drugs. Inflammatory bowel disease (IBD) defined as the patients with established diagnosis based on clinical characteristics and examination obtained with medical records, can be either Crohn’s disease or ulcerative colitis. Exclusion criteria were: (1)
review study, commentary, or viewpoint, (2) irretrievable full-text, and (3) articles in languages other than English. We sought any outcomes related to the effect of NSAID on IBD (e.g., disease relapse, worsening, progression, and NSAID as a risk factor for IBD development). Data extraction was conducted independently by two authors using Microsoft Excel software. Data extracted from each study included author name, year of publication, study design, characteristics of NSAID administration (drug name, dosing, frequency, or duration) and its comparator (control), diagnosis, number of patients, age, gender, and outcomes.

2.2 Search strategy

A literature search was conducted using available online databases, including PubMed, EMBASE, ScienceDirect, and Scopus until 1 November 2023. This review aims to evaluate the effect of NSAID administration on IBD. The following keywords were used for searching: “nonsteroidal anti-inflammatory drug”, “NSAID”, “inflammatory bowel disease”, “Crohn’s disease”, and “ulcerative colitis” with their synonyms (Table 1).

<table>
<thead>
<tr>
<th>Database</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed (Title/Abstract)</td>
<td>(Inflammatory Bowel Disease OR IBD OR Crohn’s Disease OR Ulcerative Colitis) AND (Nonsteroidal Anti-Inflammatory Drugs OR Non-steroidal Anti-Inflammatory Drugs OR nonsteroidal antiinflammatory drugs OR NSAID OR Ibuprofen OR Aspirin OR Naproxen OR Celecoxib OR Cyclo-Oxygenase Inhibitors OR cox-2 inhibitor OR cyclooxygenase-2 inhibitor OR cyclooxygenase-2 inhibitor OR analgesic)</td>
</tr>
<tr>
<td>EMBASE (Title/Abstract/Author Keyword)</td>
<td>(Inflammatory Bowel Disease OR IBD OR Crohn’s Disease OR Ulcerative Colitis) AND (Nonsteroidal Anti-Inflammatory Drugs OR Non-steroidal Anti-Inflammatory Drugs OR Non-steroidal Anti-Inflammatory Drugs OR NSAID OR Ibuprofen OR Aspirin OR Naproxen OR Celecoxib OR Cyclo-Oxygenase Inhibitors OR cox-2 inhibitor OR cyclooxygenase-2 inhibitor OR cyclooxygenase-2 inhibitor OR analgesic)</td>
</tr>
<tr>
<td>ScienceDirect (Title, Abstract, Keyword)</td>
<td>(Inflammatory bowel disease OR Crohn's Disease OR Ulcerative Colitis) AND (nonsteroidal antiinflammatory drugs OR analgesia OR NSAID OR cox-2 inhibitor OR Non-steroidal Anti-Inflammatory Drugs OR cyclooxygenase-2 inhibitor)</td>
</tr>
<tr>
<td>Scopus (Title, Abstract, Keyword)</td>
<td>( inflammatory AND bowel AND disease OR IBD OR Crohn’s OR chron AND disease OR ulcerative AND colitis ) AND ( nonsteroidal AND anti-inflammatory AND drugs OR non-steroidal AND anti-inflammatory AND drugs OR non-steroidal AND anti-inflammatory AND drugs OR nsaid OR ibuprofen OR aspirin OR naproxen OR celecoxib OR cyclooxygenase AND inhibitors OR cox-2 AND inhibitor OR cyclooxygenase-2 AND inhibitor OR cyclooxygenase-2 AND inhibitor OR analgesic )</td>
</tr>
</tbody>
</table>
2.3 Risk of bias assessment

Risk of bias assessment was conducted using the NIH quality assessment tool for each study design (e.g. controlled intervention study, observational cohort, case-control studies)[10]. Domain addressed in controlled intervention study includes randomization, treatment allocation, blinding, similarity of groups at baseline, dropout, adherence, avoiding other interventions, outcomes measures assessment, power calculation, prespecified outcomes, and intention-to-treat analysis. Domain addressed in observational cohort studies includes research question, study population, groups recruited from the same population and uniform eligibility criteria, sample size justification, exposure assessed before outcome measurement, sufficient timeframe to see an effect, different levels of the exposure of interest, exposure measures and assessment, repeated exposure assessment, outcome measures, blinding of outcome assessors, follow-up rate, and statistical analyses. Domain addressed in case-control studies include the research question, study population, target population and case representation, sample size justification, groups recruited from the same population, inclusion and exclusion criteria prespecified and applied uniformly, case and control definitions, a random selection of study participants, concurrent controls, exposure assessed before outcome measurement, exposure measures, and assessment, blinding of outcome assessors, and statistical analyses. The assessment of the study was independently performed by two authors and determined by the third author. Included studies were categorized into “good”, “fair”, or “poor”.

2.4 Statistical analysis

Data were presented in tables and figures. Data syntheses were performed using Review Manager 5.4 (Cochrane Collaboration, Oxford, England). Meta-analysis was performed to quantitatively assess the effect of non-steroidal anti-inflammatory drugs (NSAID) in inflammatory bowel disease (IBD). A random-effect model was used as there may be diverse interventions regarding of types of NSAID used between studies, which may potentiate the presence of heterogeneity in treatment effect. The effect size was calculated using the Mantel-Haenszel odds ratio (OR) and the number of events in treatment and control groups. Several events in treatment and control groups will be manually extracted from each study. Heterogeneity analyses were conducted using the Q test and I2 statistics. Subgroup analysis was performed in the study with heterogeneity.

3 Results

3.1 Study characteristics

This review included a total of 14 studies[11]–[24] for quantitative review, which consisted of 1 RCT, 4 prospective cohorts, 3 retrospective cohorts, and 6 case-control studies (Figure 1). Outcomes reported were disease relapse, disease worsening (emergency admission to hospital and IBD-related Clostridium difficile infection), progression to colorectal cancer, and risk of
development of IBD in patients receiving NSAID. Characteristics of the included study and risk of bias can be seen in Table 2.

Figure 1  Flow chart of searching strategy.
Table 2  Characteristics of included study.

<table>
<thead>
<tr>
<th>No</th>
<th>Study ID</th>
<th>Design</th>
<th>NSAID</th>
<th>Comparator/Control</th>
<th>Dose (g)/frequency/duration</th>
<th>Diagnosis</th>
<th>No. of patients</th>
<th>Age (year)</th>
<th>Male/Female</th>
<th>Rob</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Rampton 1983</td>
<td>Case-control</td>
<td>Aspirin, mefenamic acid</td>
<td>Acetaminophen</td>
<td>Aspirin: 1.2 (0.3–2.4) gram Mefenamic acid: 5 gram</td>
<td>Ulcerative colitis</td>
<td>83 (21 relapse; 62 remission)</td>
<td>Relapse = 42 (22-79); Remission = 43 (19-80)</td>
<td>Relapse: 9/12 Remission: 26/36</td>
<td>Fair</td>
</tr>
<tr>
<td>2</td>
<td>Evans 1997</td>
<td>Case-control</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>(a) current exposure, within 45 days before the index date; (b) recent exposure, between 45 and 180 days before the index date; and (c) past exposure more than 180 days before the index date</td>
<td>IBD</td>
<td>400 (case = 200; control = 200)</td>
<td>Case = 46 (9-96) Control = matched</td>
<td>N/A</td>
<td>Fair</td>
</tr>
<tr>
<td>3</td>
<td>Sandborn 2006</td>
<td>RCT</td>
<td>Celecoxib (COX-2 inhibitor)</td>
<td>Placebo</td>
<td>Celecoxib 200 mg twice daily for 14 days</td>
<td>Ulcerative colitis</td>
<td>217 (110 celecoxib group; 107 placebo group)</td>
<td>Celecoxib group = 47.2±12.15; Placebo group = 48.3±13.41 p = 0.512</td>
<td>Celecoxib group = 45% male; Placebo group = 46% male p = 0.778</td>
<td>Poor</td>
</tr>
<tr>
<td>4</td>
<td>Velayos 2006</td>
<td>Case-control</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>Use of non-prescription NSAID or aspirin</td>
<td>Ulcerative colitis</td>
<td>376 (Cases = 188; control = 188)</td>
<td>N/A</td>
<td>Case = 71% male Control = 71% male</td>
<td>Good</td>
</tr>
<tr>
<td>5</td>
<td>Meyer 2006</td>
<td>Retrospective cohort</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>At least once daily dosing of any COX inhibitor in the month before relapse or, if the patient’s IBD was in remission, in the month before the patient’s last clinic visit.</td>
<td>IBD</td>
<td>60 (relapse = 22; remission = 38)</td>
<td>Relapse = 44.6 ± 18.2</td>
<td>Remission = 52.3 ± 18.5</td>
<td>Relapse = 8/14 Remission = 16/22</td>
</tr>
<tr>
<td>6</td>
<td>Takeuchi 2006</td>
<td>Retrospective cohort</td>
<td>Naproxen, diclofenac, Indomethacin</td>
<td>Acetaminophen</td>
<td>Naproxen (500 mg twice a day), 29 on diclofenac (75 mg twice a day), and 22 on indomethacin (75 mg twice a day)</td>
<td>IBD</td>
<td>109 (32 NSAID, 26 non-NSAID)</td>
<td>Naproxen = 40 (20–70) Diclofenac = 33 (20–68) Indomethacin = 38 (24–70) Acetaminophen = 37 (24–62)</td>
<td>Naproxen = 14/18 Diclofenac = 19/10 Indomethacin = 9/13 Acetaminophen = 12/14</td>
<td>Fair</td>
</tr>
<tr>
<td>7</td>
<td>Bernstein 2010</td>
<td>Prospective cohort</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>Any use of NSAID</td>
<td>IBD</td>
<td>383 (Flare = 174; Non-flare = 209)</td>
<td>52.1±13.0 years</td>
<td>Flare 37.2% male; Non-flare 46.4% male</td>
<td>Good</td>
</tr>
<tr>
<td>8</td>
<td>Chan 2011</td>
<td>Prospective cohort</td>
<td>Aspirin</td>
<td>No aspirin</td>
<td>Any aspirin recorded ranged from 1 month to 1 year</td>
<td>Ulcerative colitis; Chron’s disease</td>
<td>CD = 35 UC = 84</td>
<td>CD = 52.7 (37.6–75.8) UC = 56.8 (35.8–77.0)</td>
<td>CD = 10/25 UC = 47/37</td>
<td>Fair</td>
</tr>
<tr>
<td>9</td>
<td>Ananthakrishnan 2012</td>
<td>Prospective cohort</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>0 tablets/week (n = 52), 0.5–1.5 tablets/week (n = 22).</td>
<td>Ulcerative colitis; Chron’s disease</td>
<td>76,795</td>
<td>56.7 (43.5–76.7)</td>
<td>All female</td>
<td>Good</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Wang 2013</td>
<td>Case-control</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>At least twice per week for at least one month.</td>
<td>Ulcerative colitis (1308 UC; 1308 control)</td>
<td>UC = 41.6 ± 12.3</td>
<td>Control = 41.4 ± 13.5</td>
<td>UC = 1.23:1 Control = 1.23:1</td>
<td>Good</td>
</tr>
<tr>
<td>11</td>
<td>Feagins 2014</td>
<td>Case-control</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>Any use of NSAID</td>
<td>IBD</td>
<td>Case = 49.0 ± 14.3</td>
<td>Control = 53.1 ± 15.7</td>
<td>p = 0.09</td>
<td>Flare: 59/7 Control: 63/5</td>
</tr>
<tr>
<td>12</td>
<td>Regnault 2014</td>
<td>Retrospective cohort</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>Taking NSAID within the two months before hospitalization</td>
<td>IBD</td>
<td>CD infection = 33 (22–46)</td>
<td>No-CD infection = 32 (25–44)</td>
<td>p = 0.85</td>
<td>CD infection = 17 (50%) male No-CD infection = 246 (55.1%) male</td>
</tr>
<tr>
<td>13</td>
<td>Hensley 2015</td>
<td>Case-control</td>
<td>All NSAIDs, Non-selective NSAIDs, Selective COX-2 inhibitors, Aspirin</td>
<td>Paracetamol</td>
<td>3 months before the assessment</td>
<td>IBD</td>
<td>Stable = 53.3 ± 15.4</td>
<td>Relapse = 47.6 ± 16.4</td>
<td>p = 0.03</td>
<td>Stable = 53.5% male Relapse = 44.1% male</td>
</tr>
<tr>
<td>14</td>
<td>Long 2016</td>
<td>Prospective cohort</td>
<td>Any NSAID</td>
<td>No NSAID</td>
<td>Exposure definitions were determined a priori and included categories of any/none and ≥5 times/monthly</td>
<td>IBD</td>
<td>791 (336 any NSAID; 455 no NSAID)</td>
<td>Any NSAID = 43.8±14.8;</td>
<td>No NSAID = 44.8±15.4</td>
<td>Any NSAID = 28.9% male No NSAID = 32.7% male</td>
</tr>
</tbody>
</table>
versus <5 times/monthly.
3.2 Disease Relapse

A total of 8 studies\cite{11,13,15–17,19–21} were included for analysis of relapse in IBD patients with NSAID medication, as seen in Figure 2. There was no significant difference in the occurrence of relapse between patients receiving NSAID and not (OR 0.97; 95% CI 0.70–1.35; \( p = 0.86 \)). Heterogeneity between studies was moderate (\( I^2 = 34\% \)).

![Figure 2](https://example.com/fig2.png)

**Figure 2** Forest plot of relapse between NSAID and control.

Subgroup analysis was performed to explore the source of heterogeneity, by categorizing studies based on their comparator to NSAID. Two studies specifically used acetaminophen as a comparator to NSAID medication, which is shown in Figure 3. No significant difference in the occurrence of relapse in patients receiving NSAID in both subgroups.

![Figure 3](https://example.com/fig3.png)

**Figure 3** Subgroup analysis between NSAID and control.

3.3 Disease worsening

A total of 2 studies\cite{12,14} were included for analysis of disease worsening in IBD patients with NSAID medication, as seen in Figure 4. NSAID was associated with a higher rate of disease...
worsening compared to patients not receiving NSAID, despite not being statistically significant (OR 2.06; 95% CI 0.92–4.57; p = 0.08). There was moderate heterogeneity between studies. This may be explained as each study uses different outcomes regarding disease worsening. Evans et al. used emergency admission to hospital in IBD patients as the outcome, while Regnault et al. used IBD-associated Clostridium infection as the outcome. Subgroup analysis cannot be performed as there were only two studies included.

3.4 Progression to colorectal cancer

One study, Velayos et al. [18] reported the association between NSAID and progression to colorectal cancer in IBD patients. NSAID may have protective effects in the progression of colorectal cancer in IBD patients (OR 0.1; 95% CI 0.03–0.5; p <0.05).

3.5 Risk of development of IBD

A total of 3 studies [22]–[24] evaluated the role of NSAID in the development of new-onset IBD from patients previously not diagnosed with either Crohn’s disease or ulcerative colitis, as seen in Figure 5. NSAID medication was significantly associated with the development of IBD (OR 1.51; 95% CI 1.19–1.92; p = 0.0008). There was no clinically important heterogeneity between studies (I2 = 25%).

4 Discussion

IBD is a chronic inflammatory disorder affecting the gastrointestinal tract with two known subtypes: Crohn’s disease and ulcerative colitis. IBD is thought to be multifactorial in origin, involving genetic, immunological, host intestinal flora, and environmental factors (e.g., smoking and medication) [1], [16]. IBD is characterized by a cycle of remission and relapse, which is
associated with significant morbidity to the patient. IBD is generally more common in Western and developed countries, but prevalence has slowly arisen in Asian countries such as Taiwan, with a prevalence of Crohn’s disease and ulcerative colitis being 2.1 per 100,000 and 12.8 per 100,000 people respectively[25].

Management of patients should focus on risk modification associated with relapse in IBD to improve patient quality of life, such as medication history of the patient. NSAIDs are among the most commonly used drugs, with approximately 60 million Americans using NSAIDs regularly[26]. It accounts for 5–10% of all prescribed medication annually[27]. It has anti-inflammatory, antipyretic, and analgesic properties, making the drugs suitable for many health conditions affecting patients of all ages[28].

Aside from its therapeutic effects, NSAID has been linked to multiple other gastrointestinal toxicities at the level of the mucosa, such as ulcers, erosions, gastrointestinal bleeding, strictures, and perforation of the bowel[28]. Histologically, NSAID-induced injury in the bowel was seen as patchy inflammation with abundant lymphoplasmacytic and neutrophil cells with slight disarray in the crypt and focal erosion[29]. It has been proposed that gastrointestinal toxicity in patients receiving NSAID was related to its inhibitory effect on prostaglandin synthesis through cyclooxygenase (COX) enzymes[30]. Prostaglandin is a hormone-like substance that is essential in the maintenance of mucosal integrity in the bowel. Inhibition of COX enzyme, specifically COX-1, may lead to impaired microcirculatory blood flow in the mucosa. COX-2 enzyme has been linked to immunomodulatory effects in the gastrointestinal tract[20].

Current literature regarding the effect of NSAIDs on IBD has brought conflicting and inconsistent results[8]. This study aims to evaluate the association between NSAID and IBD with further exploration of disease relapse, progression, and risk of development of new-onset IBD using systematic review and meta-analysis.

We did not find a significant association between NSAID medication and disease relapse and worsening of patients with underlying IBD. Disease relapse in patients receiving NSAID medication is thought to be linked with a combination of impaired mucosal microcirculatory blood flow, and mucosal defense (mucus secretion and acid regulation) related to COX-1 inhibitor. The exact mechanism by which COX-2 inhibitors induce relapse remains unknown, although delayed wound healing, increased vascular permeability, and an increase in reactive oxygen metabolites have been hypothesized to induce relapse in IBD patients. Moreover, there was evidence that the colon with colitis has upregulated COX-2 expression and its inhibition may result in exacerbation of underlying injury by triggering a delay in healing[31],[32]. Upregulation of COX-2 expression in IBD is thought to result from exposure of the cells to proinflammatory cytokines, such as interleukin-1 and TNF-α, in inflammatory conditions [33]. Other studies also reported that biopsy of colonic mucosa in patients with IBD showed an increase in the production
of prostaglandin E2 (PGE2) and PG which both have protective effects on the owner. Inhibition of COX enzymes therefore potentially harmful to the patient[34]. It needs to be highlighted that included studies in our review used different types of NSAID (including both selective and nonselective NSAID) and dosing/frequency of use. Effects of NSAID on disease relapse may be more pronounced in a higher frequency of use, as reported by Meyer et al. who showed a higher risk of relapse (adjusted OR 6.31; 95% 1.16–34.38, p = 0.03) in patients receiving NSAID as daily dose or more before relapse[19].

The risk of relapse was also higher in nonselective NSAIDs, such as ibuprofen, naproxen, diclofenac, indomethacin, or mafenamic acid compared to selective COX-2 inhibitors (celecoxib), as the drug effect was targeting both COX-1 and COX-2 inhibitors involved in the maintenance of gastrointestinal integrity[15]. Previous studies have also reported the safety of selective COX-2 inhibitors in IBD, namely celecoxib and rofecoxib, which showed that administration of selective COX-2 inhibitors is beneficial to the alleviation of symptoms in the majority of patients, although there were reversible adverse events[35]. Another study conducted by El Miedany et al showed no significant difference in mean disease activity score in patients receiving selective COX-2 inhibitor (etoricoxib given daily) compared to placebo (1.19 ± 0.683 vs 1.20 ± 0.481; p >0.05)[36]. Another study has suggested a time limit of 14 days for the use of selective COX-2 inhibitors without a greater relapse rate compared to a placebo[17]. Further study was needed to evaluate the safety of selective COX-2 inhibitors in a larger, multicenter trial.

Timing of NSAID is also important to note, as Evans et al.[12] reported higher risk of emergency admission in current (within 45 days before onset) and recent use (45 days to 180 days before onset) compared to past (more than 180 days) exposure to NSAID. The influence of NSAID dosage has also been reported by Bonner et al.[37], which showed that high-dose NSAID may result in a higher disease activity index IBD. However, an increase in disease activity index did not necessarily result in a significant increase in disease flare.

One of the included studies reported the association of NSAID and C. difficile infection[14]. Enteric infections are common in IBD patients with flare[38]. As such, the correlation between NSAID and C. difficile infection may be explained by the alteration of the intestinal barrier due to impaired microcirculation and vascular permeability, leading to patients more susceptible to infection[14], [39]. However, this study included a small number of patients. Further studies with larger samples are needed to evaluate the effect of NSAID on comorbidity associated with IBD.

Our study showed a significant association between NSAID and the development of new-onset IBD, both Crohn’s disease and ulcerative colitis. In patients without prior IBD, inhibition of COX enzymes is caused by leading to decreased prostaglandin levels. Aside from its inflammatory and pain modulation, prostaglandin has anti-inflammatory effects, in which reduction of prostaglandin would increase proinflammatory cytokines such as IL-1 and TNF-α seen in patients with Crohn’s
disease[40], [41]. Moreover, nonspecific NSAIDs also inhibit COX-1 enzymes, resulting in a disturbance in microcirculatory blood flow. The inability to maintain adequate circulation leads to an ischemic environment, which aggravates the underlying chronic inflammatory condition[22], [42]. It needs to be highlighted that one of the included studies further explored the different effects associated with aspirin and other NSAIDs as a risk factor for the development of new-onset IBD onset, in which aspirin relatively exerts COX-1-selective inhibitory effects in low to moderate doses [23]. As such, aspirin alone was not significantly associated with the occurrence of new-onset IBD in patients without prior diagnosis of IBD. Moreover, previous animal models also showed that inhibition of either COX-1 or COX-2 enzyme alone did not result in colitis, while administration of nonselective NSAID may lead to the development of colitis[43]. However, as the number of studies was limited, the association needs to be used cautiously and other confounders (e.g. family history, smoking, other medication use, previous disease) need to be taken into account.

Interestingly, there was evidence that NSAID elicited protective effects to progression to colorectal cancer[18]. IBD is categorized as an autoimmune-related gastrointestinal disease, in which the bowel is more susceptible to injury due to the immune system. Aside from its relapse and remission cycle that significantly impairs patient quality of life, patients with IBD (Crohn’s disease and ulcerative colitis) are also at a higher risk of progression to colorectal cancer. For instance, a study in North America reported that patients with Crohn’s disease and ulcerative colitis were 2.64 times (95% CI 1.69–4.12) and 2.74 times [95% CI 1.91–3.97] more likely to develop colorectal cancer, respectively[44]. The mechanism related to the progression may be explained by the rapid progression of DNA damage caused by oxidative stress in the chronic inflammatory state of IBD[45]. Morphological damage in the bowel mucosa is also prone to dysplasia formation, which further develops into carcinoma[46]. Therefore, agents that may attenuate chronic inflammation in IBD, such as NSAID, have been of particular interest as a chemoprevention of colorectal cancer.

The mechanism by which NSAIDs may exert protective effects on colorectal cancer can be explained by the COX-2 pathway. COX-2 has been known to contribute to the development of tumors through the upregulation of cell proliferation-related to prostaglandin signaling. NSAID leads to a decrease in NF-κB-mediated DNA transcription, which results in suppression of cell growth[47]. The anti-inflammatory effect of NSAID is also important as anti-the -tumor response was initiated in response to a decrease in proinflammatory cytokine, IL-1β[48], [49]. Also, COX-1 inhibition of NSAIDs, particularly aspirin leads to the inhibition of angiogenic factors and release of cytokines by platelets which may be important in chemoprevention[50]. However, as there was a potential risk of flare associated with NSAID, if patients were to be given NSAID, it should be started with low-dose NSAID drugs and not during active flare-up. Using low-dose NSAID has also been reported with overall protective effects for colorectal cancer in patients
without prior IBD diagnosis[51]. It is also beneficial to use the effective dose as it may reduce the risk of potential adverse events related to NSAID[48].

There are some limitations to this study. The heterogeneity of the included studies, particularly in terms of NSAID types, dosages, and patient demographics. The small sample sizes in some studies give rise to the need for more extensive, multicenter trials to confirm these findings. Additionally, the potential for confounding factors, such as family history, smoking, and other medication use, must be considered when interpreting the results of this review.

5 Conclusion
This study investigated the relationship between NSAID use and inflammatory bowel disease (IBD). NSAID was not associated with a significant risk of disease relapse, although there was a significant association between NSAID and the development of new-onset IBD. Given low doses, NSAIDs may exert a protective effect on colorectal cancer. However, it is important to differentiate between non-selective NSAIDs and selective COX-2 inhibitors and their dosing and frequency, and careful NSAID management should be given in IBD patients.

REFERENCES


G. Onder, F. Pellicciotti, G. Gambassi, and R. Bernabei, “NSAID-related psychiatric


